CymaBay Therapeutics Inc. (CBAY) Social Stream
CYMABAY THERAPEUTICS INC (CBAY) Price Targets From Analysts
The tables below show the price targets and recommendations analysts covering CBAY.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-10-17 | 8 | $14 | $7 | $11.125 | $23.95 | -53.55% |
| 2021-11-11 | 8 | $14 | $7 | $11.25 | $23.95 | -53.03% |
| 2022-03-18 | 8 | $14 | $9 | $11.375 | $23.95 | -52.51% |
| 2022-04-06 | 7 | $14 | $9.001 | $11.375 | $23.95 | -52.51% |
| 2022-05-13 | 7 | $14 | $9 | $11.375 | $23.95 | -52.51% |
| 2022-11-15 | 8 | $14 | $8 | $10.5 | $23.95 | -56.16% |
| 2022-12-14 | 8 | $14 | $8 | $10.25 | $23.95 | -57.2% |
| 2023-01-16 | 8 | $17 | $8 | $10.75 | $23.95 | -55.11% |
| 2023-01-31 | 8 | $19 | $8 | $12 | $23.95 | -49.9% |
| 2023-02-08 | 7 | $19 | $8 | $12.25 | $23.95 | -48.85% |
| 2023-03-16 | 8 | $19 | $8 | $12.5 | $23.95 | -47.81% |
| 2023-03-17 | 8 | $19 | $8 | $12.75 | $23.95 | -46.76% |
| 2023-03-20 | 8 | $19 | $8 | $13.375 | $23.95 | -44.15% |
| 2023-05-16 | 9 | $19 | $8 | $13.75 | $23.95 | -42.59% |
| 2023-06-30 | 9 | $19 | $8 | $14.25 | $23.95 | -40.5% |
| 2023-07-23 | 9 | $19 | $8 | $14.666 | $23.95 | -38.76% |
| 2023-07-31 | 10 | $19 | $12 | $15.555 | $23.95 | -35.05% |
| 2023-08-01 | 10 | $19 | $12 | $16.333 | $23.95 | -31.8% |
| 2023-08-11 | 11 | $20 | $12 | $16.7 | $23.95 | -30.27% |
| 2023-08-14 | 12 | $22 | $12 | $17.636 | $23.95 | -26.36% |
| 2023-08-24 | 12 | $22 | $15 | $18.181 | $23.95 | -24.09% |
| 2023-09-07 | 12 | $33 | $15 | $20.181 | $23.95 | -15.74% |
| 2023-09-08 | 12 | $33 | $18 | $21.909 | $23.95 | -8.52% |
| 2023-09-21 | 12 | $33 | $18 | $22.09 | $23.95 | -7.77% |
| 2023-09-26 | 12 | $33 | $19 | $22.727 | $23.95 | -5.11% |
| 2023-11-08 | 12 | $33 | $20 | $24 | $23.95 | 0.21% |
| 2023-11-09 | 12 | $34 | $20 | $24.454 | $23.95 | 2.1% |
| 2023-12-15 | 12 | $34 | $20 | $24.818 | $23.95 | 3.62% |
| 2023-12-19 | 12 | $34 | $20 | $25.454 | $23.95 | 6.28% |
| 2023-12-22 | 12 | $34 | $20 | $26.5 | $23.95 | 10.65% |
| 2023-12-26 | 12 | $34 | $20 | $26 | $23.95 | 8.56% |
The Trend in the Analyst Price Target
CBAY's average price target has moved up $16.6 over the prior 44 months.
CBAY reports an average of 39.06% for its upside potential over the past 49 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-03-07 | 8 | 19 | 8 | 12.500 | 9.02 | 38.58% |
| 2023-06-14 | 9 | 19 | 8 | 14.250 | 8.72 | 63.42% |
| 2023-06-30 | 9 | 19 | 8 | 14.250 | 10.95 | 30.14% |
| 2023-08-14 | 12 | 22 | 12 | 17.636 | 12.07 | 46.11% |
| 2023-12-19 | 12 | 34 | 20 | 25.454 | 22.63 | 12.48% |
CBAY Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1 | 12 | 0 | 0 | 0 | 0 | 12 |
The Trend in the Broker Recommendations
Over the past 19 months, CBAY's average broker recommendation rating improved by 0.
The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.
- In the context of all US stocks, CYMABAY THERAPEUTICS INC's upside potential (average analyst target price relative to current price) is higher than 317.51% of them.
- To contextualize these metrics, consider that out of stocks in the small market cap category, CYMABAY THERAPEUTICS INC's number of analysts covering the stock is greater than 3713.67% of them.
- CBAY has a higher average analyst price target than 1096.41% of Healthcare stocks.
- CBAY has a lower variance in analysts' estimates than -2568.4% of stocks in the small market cap category.
In the Pharmaceutical Products industry, RMTI, RIGL, and ANIP are the three stocks most similar to CYMABAY THERAPEUTICS INC regarding the price target and analyst recommendation information presented here.
View All Top Stocks by Price Target
Is CBAY a Buy, Hold or Sell? See the POWR Ratings now!